SureTrader Advertisement
Home > Boards > US Listed > Biotechs > Ariad Pharmaceuticals, Inc. (ARIA)

That would be logical once the anecdotal reports

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
vidpok45 Member Profile
 
Followed By 21
Posts 4,241
Boards Moderated 0
Alias Born 06/15/10
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/29/2016 4:27:02 PM
ARIAD Announces Webcast of Its Annual Stockholders Meeting "Business Wire" - 6/24/2016 7:35:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/23/2016 4:13:32 PM
ARIAD Completes Strategic Review and Announces Plans for Growth "Business Wire" - 6/17/2016 12:33:00 PM
ARIAD Announces Distribution Agreements for Iclusig® in Latin America and the Middle East/North Africa "Business Wire" - 6/17/2016 7:45:00 AM
ARIAD Initiates Submission of New Drug Application for Brigatinib to the U.S. Food and Drug Administration Ahead of Plan "Business Wire" - 6/17/2016 7:35:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/15/2016 4:20:44 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/14/2016 6:14:12 PM
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial "Business Wire" - 6/13/2016 7:35:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 6/8/2016 4:11:40 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/8/2016 4:10:17 PM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 6/8/2016 4:08:59 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 6/8/2016 4:08:08 PM
ARIAD to Host Analyst & Investor Day in New York City "Business Wire" - 6/8/2016 7:35:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/7/2016 4:09:07 PM
ARIAD's Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate & 12.9-Month Median Pro... "Business Wire" - 6/6/2016 7:35:00 AM
ARIAD Presents Long-Term Phase 1/2 Trial Follow up on Investigational Drug Brigatinib with Median Time on Treatment of 17 Mon... "Business Wire" - 6/4/2016 7:35:00 AM
ARIAD Presents Data from Mutational Profiling in Crizotinib-Resistant Patients Treated with Investigational Medicine Brigatin... "Business Wire" - 6/4/2016 7:35:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/2/2016 8:31:45 AM
ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig® "Business Wire" - 6/2/2016 7:35:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/1/2016 4:55:42 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 6/1/2016 4:53:33 PM
ARIAD to Present at the Jefferies 2016 Global Healthcare Conference "Business Wire" - 6/1/2016 7:35:00 AM
ARIAD Announces Initiation of Phase 1/2 Clinical Trial of AP32788, an Investigational Oral Inhibitor of EGFR & HER2, in Patie... "Business Wire" - 5/31/2016 7:35:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) "Edgar (US Regulatory)" - 5/27/2016 5:16:34 PM
vidpok45   Tuesday, 05/15/12 08:11:15 PM
Re: ariadndndough post# 18930
Post # of 74350 
That would be logical once the anecdotal reports can be validated.

SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist